Immunisation references

  1. 普罗金,年代. A. 等. The science of vaccine safety: Summary of meeting at Wellcome Trust. 在疫苗卷. 38 1869–1880 (Elsevier Ltd, 2020).
  2. 普罗金,年代.奥仁斯坦W. & Offit P. 疫苗. The Lancet 感染ious 说eases vol. 8 (Elsevier, 2008).
  3. Roush,年代. W. 等. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. Journal of the American 地中海ical Association vol. 298 2155–2163 (2007).
  4. 西蒙斯,E. 等. Assessment of the 2010 global measles mortality reduction goal: Results from a model of surveillance data. Lancet 379, 2173–2178 (2012).
  5. ASCIA Acute Management of Anaphylaxis. www.过敏.org.au/hp/papers/acute-management-of-anaphylaxis-in-pregnancy (2020).
  6. 波拉德,. J. & bijk E. M. A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology vol. 21 83–100 (2020).
  7. 柠檬,年代. M. & 托马斯,维. L. 疫苗 to Prevent Viral Hepatitis. N. 心血管病. J. 地中海. 336, 196–204 (1997).
  8. Neuzil K. M.、杜邦、W. D.赖特,P. F. & 爱德华兹,K. M. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: The pediatric experience. Pediatr. 感染. 说. J. 20, 733–740 (2001).
  9. Stratton K.福特,.Rusch E. & 克莱顿,E. W. Adverse effects of vaccines: Evidence and causality. Adverse Effects of 疫苗: Evidence and Causality (National Academies Press, 2012). doi: 10.17226/13164.
  10. 巴洛,W. E. 等. The Risk of Seizures after Receipt of Whole-Cell Pertussis or Measles, 流行性腮腺炎, and Rubella 菌苗e. N. 心血管病. J. 地中海. 345, 656–661 (2001).
  11. Mantadakis E.Farmaki E. & 布坎南,G. R. Thrombocytopenic Purpura after Measles-流行性腮腺炎-Rubella 菌苗ation: A Systematic Review of the Literature and Guidance for Management. J. Pediatr. 156, 623–628 (2010).
  12. Perry R. T. & 哈尔西N. A. The clinical significance of measles: A review. Journal of 感染ious 说eases vol. 189 (2004).
  13. Pulendran B. & 艾哈迈德,R. Immunological mechanisms of vaccination. Nature Immunology vol. 12 509–517 (2011).
  14. 斯托J.安德鲁斯,N.,明智的,L. & 米勒,E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database. Am. J. 论文. 169, 382–388 (2009).
  15. 幽灵,D. C.高盛,米. & 兰伯特,P. H. 菌苗ation and autoimmune disease: What is the evidence? 柳叶刀》卷. 362 1659–1666 (2003).
  16. 爱,B. 等. Molecular biology of the cell. Biochemistry and Molecular Biology 教育 vol. 36 (Wiley, 2008).
  17. 墨菲,K. M.,特拉弗斯. & Walport米. Janeway’s Immunobiology. (Garland Science, 2007).
  18. Banchereau J. & 斯坦曼R. M. Dendritic cells and the control of immunity. 自然卷. 392 245–252 (1998).
  19. 米勒,J. F. Immunological function of the thymus. Lancet 278, 748–749 (1961).
  20. 米勒,J. F. & 米切尔,克. F. Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. J. 经验值. 地中海. 128, 801–820 (1968).
  21. Roitt,我. M.油渣,米. F., Torrigiani, G.、Brostoff J. & 公平联盟,J. H. The cellular basis of immunological responses. A synthesis of some current views. 柳叶刀》卷. 2 367–371 (1969).
  22. Zinkernagel R. M. & 多尔蒂,P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701–702 (1974).
  23. 伯内特,F. M. The Clonal Selection Theory of Acquired Immunity. (Cambridge University Press, 1959).
  24. 艾哈迈德,R. & 灰色,维. Immunological memory and protective immunity: Understanding their relation. 科学(80 -. ). 272, 54–60 (1996).
  25. Sallusto F., Lanzavecchia, A.荒木,K. & 艾哈迈德,R. From vaccines to memory and back. 免疫期. 33 451–463 (2010).
  26. Panum L. P. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Bibiliothek for Laeger 3R, 270–344 (1847).
  27. Adkins, B.勒克莱尔C. & Marshall-Clarke, S. Neonatal adaptive immunity comes of age. Nature Reviews Immunology vol. 4 553–564 (2004).
  28. 陈,R. T. 等. Measles Antibody: Reevaluation of Protective Titers. J. 感染. 说. 162, 1036–1042 (1990).
  29. Schauer U. 等. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. 中国. 成岩作用. 实验室. Immunol. 10, 202–207 (2003).
  30. 韦贝尔,R. E.斯托克斯,J.Buynak E. B.惠特曼,J. E. & 希勒曼,M. R. Live, Attenuated 流行性腮腺炎-Virus 菌苗e. N. 心血管病. J. 地中海. 276, 245–251 (1967).
  31. Offit P. A. & 犹太人,R. K. Addressing Parents’ Concerns: Do 疫苗 Contain Harmful Preservatives, 佐剂, 添加剂, 或残差? 儿科卷. 112 1394–1401 (2003).
  32. 石头,C. A. 等. Anaphylaxis after zoster vaccine: Implicating alpha-gal 过敏 as a possible mechanism. J. 过敏的中国. Immunol. 139, 1710-1713.e2 (2017).
  33. 石头,C. A. 等. Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal 过敏. J. 过敏的中国. Immunol. Pract. 7, 322-324.e2 (2019).
  34. Delrue,我.Verzele D.茜草属的植物,. & Nauwynck H. J. Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges. 经验值ert Review of 疫苗 vol. 11 695–719 (2012).
  35. 枯燥、P. M. & 麦金托什,E. D. Meningococcal vaccine development - from glycoconjugates against MenACWY to proteins against MenB - potential for broad protection against meningococcal disease. 菌苗e 30, (2012).
  36. 帕克曼,P. D. & 老板霍普,H. E. Viral vaccines and antivirals: 咕咕叫ent use and future prospects. Annual Review of Public Health vol. 9 203–221 (1988).
  37. Zuckerman,. J. Subunit, recombinant and synthetic hepatitis b vaccines. Scand. J. 杂志. 20, 27–38 (1985).
  38. Avci F. Y.李X.信,米. & Kasper D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. 地中海. 17, 1602–1609 (2011).
  39. 罗兰,. S.琼斯,J. O. & Andino R. Rationalizing the development of live attenuated virus vaccines. Nature Biotechnology vol. 28 573–579 (2010).
  40. Edelman R. 菌苗e adjuvants. Reviews of infectious diseases vol. 2 370–383 (1980).
  41. 爱因斯坦,米. H. 等. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. 嗡嗡声. 菌苗. 5, 705–719 (2009).
  42. 戴伊,. 等. Surveillance of adverse events following immunisation in 欧斯特ralia: annual report, 2018. Commun. 说. 智能. 44, (2020).
  43. 麦克尼尔,M. M. 等. Risk of anaphylaxis after vaccination in children and adults. J. 过敏的中国. Immunol. 137, 868–878 (2016).
  44. Imafidon G. I. & Sosulski F. W. Nucleic Acid Nitrogen of Animal and Plant Foods. J. 阿格利司. 食品化学. 38, 118–120 (1990).
  45. 威尔逊,维.小P. D.阿夫扎尔,米. A. & Ghosh,年代. Detection of persistent measles virus infection in Crohn’s disease: 咕咕叫ent status of experimental work. 肠道卷. 48 748–752 (2001).
  46. Khakoo G. A. & 缺乏,G. Recommendations for using MMR vaccine in children allergic to eggs. BMJ Br. 地中海. J. 320, 929 (2000).
  47. 马林斯R. J.坎普,. & 黄金,米. Influenza vaccination of the egg-allergic individual. 地中海ical Journal of 欧斯特ralia vol. 193 254–255 (2010).
  48. Davidkin,我.Kontio,米.Paunio,米. & Peltola H. MMR vaccination and disease elimination: The finnish experience. 经验值ert Review of 疫苗 vol. 9 1045–1053 (2010).
  49. 坎贝尔,H.安德鲁斯,N.、棕色、K. E. & 米勒,E. Review of the effect of measles vaccination on the epidemiology of SSPE. International Journal of 论文ogy vol. 36 1334–1348 (2007).
  50. Nebbia G.粉红,维. & Maini, M. K. Hepatitis B infection: 咕咕叫ent concepts and future challenges. QJM卷. 105 109–113 (2012).
  51. 波尔,年代., Vallet-Pichard, A.Corouge,米. & 锤,V. O. Hepatitis C: 论文ogy, diagnosis, natural history and therapy. Contributions to Nephrology vol. 176 1–9 (2012).
  52. El-Serag H. B. Hepatocellular Carcinoma. N. 心血管病. J. 地中海. 365, 1118–1127 (2011).
  53. McLaughlin-Drubin, M. E.迈耶斯,J. & 芒格,K. Cancer associated human papillomaviruses. 咕咕叫ent 当今ion in Virology vol. 2 459–466 (2012).
  54. Schiffman, M.城堡,P. E.、Jeronimo J.罗德里格斯,. C. & Wacholder,年代. 嗡嗡声an papillomavirus and cervical cancer. 柳叶刀》卷. 370 890–907 (2007).
  55. Kimberlin D. W. & 惠特利,R. J. Varicella–Zoster 菌苗e for the Prevention of Herpes Zoster. N. 心血管病. J. 地中海. 356, 1338–1343 (2007).
  56. 金,T. H.约翰斯通,J. & Loeb, M. 菌苗e herd effect. Scandinavian Journal of 感染ious 说eases vol. 43 683–689 (2011).
  57. 西蒙,. K.荷兰人,克. A. & 一个麦克. Evolution of the immune system in humans from infancy to old age. Proceedings of the Royal Society B: Biological Sciences vol. 282 (2015).
  58. 卡恩,C. R. Perverted priorities. The physician/scientist as spokesman and salesman for biomedical research. Presidential address to the American Society for 中国ical Investigation, 华盛顿, DC, 1989年4月29日. The Journal of clinical investigation vol. 84 723–727 (1989).
  59. World Health Organisation. Hepatitis B vaccines. http://www.who.int/immunization/HepB_position_paper_oct09_summary.pdf (2009).
  60. 佩特洛娃,V. N. 等. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci. Immunol. 4, 6125 (2019).
  61. 米娜,M. J. 等. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. 科学(80 -. ). 366, 599–606 (2019).
  62. 拜尔,W. E. P.Palache,. M.kersten, R. & Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. 欧元. J. 中国. Microbiol. 感染. 说. 15, 65–70 (1996).
  63. Peltola H. & 阿,Heinonen. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 327, 939–942 (1986).
  64. 克莱恩,N. P. 等. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 126, (2010).
  65. 帕克,年代. K.施瓦兹,B.托德,我. & 皮克林,L. K. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. Pediatrics 114, 793–804 (2004).
  66. Poehling K. A. 等. The Underrecognized Burden of Influenza in Young Children. N. 心血管病. J. 地中海. 355, 31–40 (2006).
  67. 阿白,. J. 等. A genomics-based approach to assessment of vaccine safety and immunogenicity in children. 菌苗e 30, 1865–1874 (2012).
  68. 安德烈,F. 等. 菌苗ation greatly reduces disease, disability, death and inequity worldwide. 人(2011).
  69. Rappuoli R.Mandl C. W.,黑色,年代. & 德格雷戈里奥,E. 疫苗 for the twenty-first century society. Nature Reviews Immunology vol. 11 865–872 (2011).
  70. Monto,. S. & 皮特里,J. G. Improving Influenza 菌苗e Effectiveness: Ways to Begin Solving the Problem. 中国ical 感染ious 说eases vol. 69 1824–1826 (2019).
  71. 李,N.彭,我. H.陈X.中川,年代. & 高,我. Q. Transcutaneous vaccines: Novel advances in technology and delivery for overcoming the barriers. 疫苗卷. 29 6179–6190 (2011).
  72. Van Der Maaden, K.Jiskoot W. & Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. Journal of Controlled Release vol. 161 645–655 (2012).
  73. Mbow, M. L., 德格雷戈里奥,E.Valiante N. M. & Rappuoli R. New adjuvants for human vaccines. 咕咕叫ent 当今ion in Immunology vol. 22 411–416 (2010).
  74. Rybicki E. P. Plant-produced vaccines: promise and reality. Drug 说covery Today vol. 14 16–24 (2009).
  75. 的花环,年代. M. 等. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. 中国. 疫苗Immunol. 14, 792–795 (2007).
  76. 韦贝尔,R. E.Buynak E. B.麦克莱恩,. A. & 希勒曼,M. R. Long-Term Follow-up for Immunity After Monovalent or Combined Live Measles, 流行性腮腺炎, and Rubella Virus 疫苗. Pediatrics 56, (1975).
  77. Rappuoli R. & Aderem,. A 2020 vision for vaccines against HIV, tuberculosis and malaria. 自然卷. 473 463–469 (2011).
  78. Rupnow, M. F. T.常,. H.Shachter, R. D.欧文斯D. K. & Parsonnet J. Cost-effectiveness of a potential prophylactic helicobacter pylori vaccine in the united states. J. 感染. 说. 200, 1311–1317 (2009).
  79. 豪伊,年代. E. M.霍纳P. J.霍恩,. W. & Entrican G. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. 咕咕叫. 当今. 感染. 说. 24, 56–61 (2011).
  80. 当然喽,.霍根,米. J.波特F. W. & 斯曼,D. mRNA vaccines-a new era in vaccinology. Nature Reviews Drug 说covery vol. 17 261–279 (2018).
  81. Nossal G. J. V. 疫苗 of the future. 菌苗e 29, (2011).
  82. Cucinotta D. & Vanelli, M. WHO declares COVID-19 a pandemic. Acta Biomedica vol. 91 157–160 (2020).
  83. 中文版由米. C. & 菲利普斯,E. J. Maintaining Safety with SARS-CoV-2 疫苗. N. 心血管病. J. 地中海. 384, 643–649 (2021).
  84. Petousis-Harris, H. & 小巷里,我. Impact of antivaccination campaigns on health worldwide: lessons for 欧斯特ralia and the global community. 地中海. J. 欧斯特. 213, 300-301.e1 (2020).
  85. 张,E. J.Chughtai,. A.海伍德,. & 麦金太尔,C. R. Influence of political and medical leaders on parental perception of vaccination: A cross-sectional survey in 欧斯特ralia. BMJ Open 9, e025866 (2019).
  86. Leask J. 等. Communicating with parents about vaccination: a framework for health professionals. BMC 儿科卷. 12 154 (2012).
  87. 布鲁尔N. T.,查普曼,G. B.Rothman,. J.、Leask J. & 肯普,. Increasing 菌苗ation: Putting Psychological Science Into Action. Psychol. Sci. 公共利益. 18, 149–207 (2017).

 

© 2022 欧斯特ralian Academy of Science